Exscientia Announces Collaboration with Charité
Wednesday, March 08, 2023
Exscientia announced a new collaboration with Charité – University Medicine Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.
Under the collaboration, Charité will evaluate the potential of Exscientia’s precision medicine platform to select better treatments and improve outcomes for patients with haematological cancers. Each patient sample will be prospectively evaluated with a broad panel of marketed drugs, including drugs that have not yet approved for the indication, to determine a comparative response profile, ex vivo.
EXALT-1 was a first-of-its-kind prospective trial, which demonstrated significantly improved outcomes for late-stage haematological cancer patients using Exscientia's deep learning-based high content functional drug testing platform to guide personalised treatment recommendations as compared to physician’s choice of treatment.
Despite major advances in the treatment of haematological cancers, the mortality rate for patients suffering from these conditions remains high. Based on the results of the EXALT-1 trial, this new collaboration with Exscientia likely provides an opportunity to further explore ways to significantly improve treatment and patient outcomes. Moreover, with the success of the EXALT-1 trial, AI-guided treatment has the potential to significantly improve patient outcomes, as well as healthcare economics.
